Biomarkers and Target Therapy for Lung Cancer

Precision (target) medicine is proposed as a new strategy to identify and develop highly selective drugs against specific targets for the disease more precise tailoring of medicines target populations patients. can be an important approach create novel safer therapeutics (tyrosine kinase inhibitors, tumour monoclonal antibodies) patients with gene mutation, aberrations, or protein over-expression. requires understanding mutational processes, heterogeneity between cancer cells during tumor evolution. The present review briefly define various heterogeneities potential associations drug efficacy resistance, emphasize importance functional biomarkers monitor opportunities challenges precision clinical practice.